The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its 2026 Board officers after elections held during the organization’s December 2025 Board meeting, a milestone that underscores how this relatively young global initiative is solidifying its position in promoting scientifically robust, human‑relevant alternatives to animal testing in cosmetics safety assessment. The newly selected leadership reflects continuity as well as the organization’s growing sophistication, building on a year of significant accomplishments while positioning itself to expand its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Leadership continuity and global representation
The 2026 Board leadership unites senior leaders from the cosmetics, consumer goods, and regulatory advocacy fields, capturing the multi-stakeholder character that has shaped ICCS from the start. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been chosen again to serve as Chair of the Board of Directors. His renewed appointment reflects sustained trust in a leadership style grounded in scientific rigor, international collaboration, and productive dialogue with regulatory authorities.
Serving with him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose extensive record in industry advocacy and regulatory collaboration delivers a solid regional perspective shaped by policy expertise. The position of Secretary will be taken on by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, contributing wide-ranging knowledge in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been named Treasurer, providing deep leadership experience in toxicology and organizational governance.
Acting collectively, the officers form a Board leadership team whose broad background spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than a champion of any specific industry. This balance supports the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Driving progress in animal-free science through collective collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
Throughout 2025, ICCS introduced a range of initiatives that reinforced its scientific base and broadened its reach. Among these efforts was the publication of a Best Practice Guidance document, created to offer clearer direction and greater uniformity in applying animal-free safety assessment methods. The guidance sought to connect scientific advances with regulatory needs, delivering a practical framework that stakeholders could use when generating or reviewing non‑animal evidence.
In parallel, ICCS contributed to shaping new methodologies consistent with next generation risk assessment (NGRA), an evolving framework that draws on advanced in vitro, in silico, and exposure-driven strategies. These methods are now widely regarded as fundamental to contemporary toxicology, offering more human-relevant insights while limiting dependence on animal studies. ICCS’ engagement in this field underscores its dedication to promoting both ethical progress and scientific rigor.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A pivotal moment for cosmetics safety regulation
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has long underscored that moving toward animal‑free safety science cannot progress through isolated initiatives; rather, it demands synchronized engagement from industry, academia, regulatory bodies, and civil society. The Board’s makeup embodies this principle by uniting figures who grasp the technical, regulatory, and organizational aspects required to drive meaningful transformation.
Statements from ICCS leadership after the elections expressed both assurance and realism, highlighting the advances made in recent years while acknowledging that significant hurdles remain. They noted that securing broad regulatory approval for animal-free methods will continue to require ongoing research funding, transparent data exchange, and steady cooperation with authorities to respond to legitimate questions about reliability, practical applicability, and the protection of public health.
The re-elected Chair emphasized the vital need to rely on ICCS’ global, multi-stakeholder framework to close the gap between innovation and regulation, ensuring that advances in animal-free science extend beyond the laboratory and evolve into dependable, consistently implemented tools that regulators can trust.
Reinforcing the groundwork for lasting influence
As ICCS moves toward 2026 and the years that follow, the organization aims to reinforce its progress while broadening its influence, and the newly appointed Board leadership is anticipated to guide key priorities that balance scientific aspirations with practical execution, including pinpointing topics that require further direction or consensus, backing the validation and dissemination of emerging methodologies, and promoting global harmonization to minimize fragmentation among regulatory expectations.
Education stands as another fundamental component of ICCS’ strategy. By offering accessible, science-grounded materials and spaces for dialogue, the organization seeks to clarify animal-free safety science and support well-informed choices. This remains crucial in a discipline where misunderstandings or uneven knowledge can hinder advancement, even when the core science is robust.
The organization’s structure, encompassing leading cosmetics and ingredient producers alongside trade and research groups as well as animal protection organizations, places it in a distinctive position to tackle these challenges. This broad range of viewpoints helps keep discussions balanced, well‑rooted, and oriented toward common objectives rather than limited agendas.
Based in New York, ICCS remains active as a global initiative that underscores the inherently international landscape of cosmetics research and regulation. As products and ingredients frequently cross national borders, aligning standards and encouraging mutual acceptance of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science around the world.
By confirming its 2026 Board officers, ICCS underscores stability while hinting at ongoing advancement, with its leadership team providing steady direction after a year marked by concrete achievements and the seasoned perspective needed to guide the next stage of transformation; as scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a unifying hub and driving force for animal-free cosmetics safety science is set to become even more influential.
Ultimately, the importance of the 2026 Board elections rests not only on who is selected, but also on what their leadership conveys: a continued dedication to cooperation, scientific rigor, and the ethical progress of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn ambition into enduring results, guiding the evolution of cosmetics safety in a manner that brings ethics, scientific excellence, and global public confidence into alignment.
